title: Optimized quantification of lymphocyte subsets by use of CD7 and CD33.
abstract: Identification and quantification of lymphocyte subsets is based on the expression of specific cell surface antigens. As only a minority of these structures is lineage-restricted gating strategies were established, which should permit to include a maximum of lymphocytes, to reach a high purity within the gate and to avoid specific loss of subsets. Two problems remain: First, the incomplete removal of nonlymphoid cells when CD14 is used to exclude them from the lymphocyte gate. Second, the lack of a restricted marker to identify NK cells that are usually defined as CD3(-) /CD16/56(+) lymphocytes, though contaminating monocyte subsets share the expression of CD16, respectively, CD56. This study demonstrates the advantage of CD33 over CD14 at the creation of a pure lymphocyte gate, because CD33 enables the exclusion of all monocyte subpopulations as well as basophils and granulocytes. Independent of the applied NK cell marker mean purity was significantly higher, when CD33 was used (P < 0.001). For the identification of NK cells, CD7 was compared with CD16/56 and with single stained CD56. CD7 and CD16/56 exhibited as equivalent in various CD33 settings (P ≥ 0.173), whereas the mean proportion of CD56(+) NK cells was significantly lower (P ≤ 0.008). Use of CD14 entailed a significantly higher amount of CD3(-) /CD16/56(+) cells than of CD3(-) /CD7(+) cells (P = 0.008) because of the remaining CD14(-) /CD16(+) monocytes. As CD7 is restricted to T cells and NK cells in peripheral blood, misclassification of contaminating monocytes is avoided and CD7(+) NK cells can be identified by lack of CD3. Applying this new selection of mAbs, we reached a mean purity of ≥99.50% within the revised lymphocyte gate. As gates can be set very broadly, high inclusivity and high purity are not mutually exclusive. We propose the adoption of CD7 and CD33 for the quantification of lymphocyte subsets.
authors: Department of Laboratory Medicine, Donauspital, 1220 Vienna, Austria. andrea.hauser@wienkav.at
authors: Andrea
authors: A
authors: Hauser
authors: Karl
authors: K
authors: Schrattbauer
authors: Djurdjica
authors: D
authors: Najdanovic
authors: Regina
authors: R
authors: Schlossnickel
authors: Astrid
authors: A
authors: Koch
authors: Milos
authors: M
authors: Hejtman
authors: Walter
authors: W
authors: Krugluger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D019011:Antigens, CD7 / Q000032:analysis; D000954:Antigens, Surface / Q000276:immunology*; D017252:CD3 Complex / Q000032:analysis; D019002:CD56 Antigen / Q000032:analysis; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D005453:Fluorescence; D006801:Humans; D007694:Killer Cells, Natural / Q000166:cytology*; D016131:Lymphocyte Subsets / Q000166:cytology*; D008297:Male; D008875:Middle Aged; D017452:Receptors, IgG / Q000032:analysis; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000032:analysis; D013194:Staining and Labeling
chemical_list: D000911:Antibodies, Monoclonal; D019011:Antigens, CD7; D000954:Antigens, Surface; D017252:CD3 Complex; D019002:CD56 Antigen; D017452:Receptors, IgG; D063268:Sialic Acid Binding Ig-like Lectin 3